These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22977660)

  • 41. Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.
    Matsuo Y; Tashiro H; Yanai H; Moriya T; Katabuchi H
    Med Mol Morphol; 2015 Sep; 48(3):146-54. PubMed ID: 25398420
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.
    Anglesio MS; Bashashati A; Wang YK; Senz J; Ha G; Yang W; Aniba MR; Prentice LM; Farahani H; Li Chang H; Karnezis AN; Marra MA; Yong PJ; Hirst M; Gilks B; Shah SP; Huntsman DG
    J Pathol; 2015 Jun; 236(2):201-9. PubMed ID: 25692284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Upregulation of fibronectin following loss of p53 function is a poor prognostic factor in ovarian carcinoma with a unique immunophenotype.
    Yokoi A; Matsumoto T; Oguri Y; Hasegawa Y; Tochimoto M; Nakagawa M; Saegusa M
    Cell Commun Signal; 2020 Jul; 18(1):103. PubMed ID: 32635925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HNF-1β in ovarian carcinomas with serous and clear cell change.
    DeLair D; Han G; Irving JA; Leung S; Ewanowich CA; Longacre TA; Gilks CB; Soslow RA
    Int J Gynecol Pathol; 2013 Nov; 32(6):541-6. PubMed ID: 24071869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas.
    Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
    Mod Pathol; 2012 Jan; 25(1):122-30. PubMed ID: 21983935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
    Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
    Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear cell-type versus endometrioid-type adenocarcinoma.
    Kajihara H; Yamada Y; Shigetomi H; Higashiura Y; Kobayashi H
    Int J Gynecol Pathol; 2012 Jul; 31(4):304-12. PubMed ID: 22653342
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations.
    Munksgaard PS; Blaakaer J
    Gynecol Oncol; 2012 Jan; 124(1):164-9. PubMed ID: 22032835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The malignant potential of ovarian atypical endometriosis].
    Guo L; Liu T; Lang J
    Zhonghua Bing Li Xue Za Zhi; 2001 Jun; 30(3):169-72. PubMed ID: 11866970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical Comparison of Ovarian and Uterine Endometrioid Carcinoma, Endometrioid Carcinoma With Clear Cell Change, and Clear Cell Carcinoma.
    Lim D; Ip PP; Cheung AN; Kiyokawa T; Oliva E
    Am J Surg Pathol; 2015 Aug; 39(8):1061-9. PubMed ID: 25871622
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis.
    Fuseya C; Horiuchi A; Hayashi A; Suzuki A; Miyamoto T; Hayashi T; Shiozawa T
    Hum Pathol; 2012 Nov; 43(11):1964-72. PubMed ID: 22626277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells.
    Lakshminarasimhan R; Andreu-Vieyra C; Lawrenson K; Duymich CE; Gayther SA; Liang G; Jones PA
    Cancer Lett; 2017 Aug; 401():11-19. PubMed ID: 28483516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary.
    Davis M; Rauh-Hain JA; Andrade C; Boruta DM; Schorge JO; Horowitz NS; May T; del Carmen MG
    Gynecol Oncol; 2014 Mar; 132(3):760-6. PubMed ID: 24440832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular pathogenesis of ovarian clear cell carcinoma.
    Gounaris I; Brenton JD
    Future Oncol; 2015; 11(9):1389-405. PubMed ID: 25952785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8
    Heinze K; Nazeran TM; Lee S; Krämer P; Cairns ES; Chiu DS; Leung SC; Kang EY; Meagher NS; Kennedy CJ; Boros J; Kommoss F; Vollert HW; Heitz F; du Bois A; Harter P; Grube M; Kraemer B; Staebler A; Kommoss FK; Heublein S; Sinn HP; Singh N; Laslavic A; Elishaev E; Olawaiye A; Moysich K; Modugno F; Sharma R; Brand AH; Harnett PR; DeFazio A; Fortner RT; Lubinski J; Lener M; Tołoczko-Grabarek A; Cybulski C; Gronwald H; Gronwald J; Coulson P; El-Bahrawy MA; Jones ME; Schoemaker MJ; Swerdlow AJ; Gorringe KL; Campbell I; Cook L; Gayther SA; Carney ME; Shvetsov YB; Hernandez BY; Wilkens LR; Goodman MT; Mateoiu C; Linder A; Sundfeldt K; Kelemen LE; Gentry-Maharaj A; Widschwendter M; Menon U; Bolton KL; Alsop J; Shah M; Jimenez-Linan M; Pharoah PD; Brenton JD; Cushing-Haugen KL; Harris HR; Doherty JA; Gilks B; Ghatage P; Huntsman DG; Nelson GS; Tinker AV; Lee CH; Goode EL; Nelson BH; Ramus SJ; Kommoss S; Talhouk A; Köbel M; Anglesio MS
    J Pathol; 2022 Apr; 256(4):388-401. PubMed ID: 34897700
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ovarian carcinomas in endometriosis: an immunohistochemical and comparative genomic hybridization study.
    Mhawech P; Kinkel K; Vlastos G; Pelte MF
    Int J Gynecol Pathol; 2002 Oct; 21(4):401-6. PubMed ID: 12352189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.
    Kao YC; Lin MC; Lin WC; Jeng YM; Mao TL
    Histopathology; 2012 Nov; 61(5):760-8. PubMed ID: 22747504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
    Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
    Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases.
    DeLair D; Oliva E; Köbel M; Macias A; Gilks CB; Soslow RA
    Am J Surg Pathol; 2011 Jan; 35(1):36-44. PubMed ID: 21164285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.